Serum IL-1ra Is Associated with but Has No Genetic Link to Type 1 Diabetes

Interleukin-1 antagonism is a proposed biomarker and potential therapy for the delay and/or treatment of type 1 diabetes (T1D). We evaluated role circulating interleukin-1 receptor antagonist (IL-1ra) in prospectively monitored cohort T1D patients. In order to determine mechanistic association between IL-1ra T1D, we performed co-localization analyses serum protein quantitative trait loci genome-wide analysis studies. Adjusting human leukocyte antigen (HLA) genotypes, first degree relative status, gender, age, levels were lower subjects who progressed compared controls (p = 0.023). Our results suggest that females have higher males 0.005). The 2q14.1 region associated with not risk developing T1D. data IL-1 by an effective but may be progression